Bristol Myers Squibb Stock Rises on Strong Q2 Earnings
On Thursday, Bristol Myers Squibb (NYSE: BMY) reported strong second-quarter earnings that outperformed analyst expectations and drove a significant rise in its stock price. The company's revenue reached $12.97 billion for the quarter—a year-over-year increase of 6%. Adjusted net income surged to $4.2 billion, or $2.04 per share, up from $3 billion in the same period last year. The growth was largely driven by Bristol Myers Squibb's successful drug portfolio, particularly its blockbuster immunotherapy Opdivo, which generated nearly $2.5 billion in global sales during the quarter. The company also raised its 2026 revenue and earnings guidance due to these strong results, signaling continued confidence in future performance. Investors responded positively by pushing BMY's stock up almost 2.8%, outpacing a 1.5% rise in the S&P 500 index.
Tickers: $BMY
Topics: financial_performance pharmaceuticals